🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Tong Ren Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai Tong Ren Hospital as lead sponsor. Synced 26 Sep 2026
7Current trials
5Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Tong Ren Hospital is the lead sponsor of 7 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Azacitidine, Selinexor and Venetoclax. The most-studied condition is Pacing Therapy.

ClinicalTrials.gov trials by status

  • Recruiting571%
  • Not yet open114%
  • By invitation114%

Trials by phase

  • Not applicable343%
  • Phase 2229%
  • Phase 4229%
01

Clinical trials sponsored by Shanghai Tong Ren Hospital

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
NCT05736965 · ClinicalTrials.gov ↗ · AML, Adult
Phase 2 Recruiting 2023-02 China
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
NCT05736978 · ClinicalTrials.gov ↗ · AML, MRD
Phase 2 Recruiting 2023-03 China
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
NCT05292404 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction
Phase 4 Recruiting 2022-10 China
Immediate Electrophysiological Effects of Different Atrial Pacing Sites on P-Wave Characteristics
NCT07603648 · ClinicalTrials.gov ↗ · Pacing Therapy, Cardiac Pacing
Not applicable Recruiting 2026-03 China
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
NCT04731155 · ClinicalTrials.gov ↗ · Early PCSK9 Inhibitor on Ventricular Remodling
Phase 4 Recruiting 2021-04 China
Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction
NCT07645066 · ClinicalTrials.gov ↗ · Pacing Therapy, Cardiac Pacing
Not applicable Not yet open 2026-08 China
The Prognosis Effect of Indocyanine Green (ICG) Fluorescence Guided Surgery on Disease-free Survival (DFS) of Stage III Colorectal Cancer
NCT06583564 · ClinicalTrials.gov ↗ · Colorectal Cancer Stage III
Not applicable By invitation 2024-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Tong Ren Hospital trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Tong Ren Hospital trials

8 conditions
Pacing Therapy2Cardiac Pacing2AML, Adult1AML1MRD1Acute Myocardial Infarction1Colorectal Cancer Stage III1Early PCSK9 Inhibitor on Ventricular Remodling1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China75

A trial with sites in more than one country appears in each of those registers.

05

Questions about Shanghai Tong Ren Hospital trials

How many clinical trials does Shanghai Tong Ren Hospital sponsor?

Shanghai Tong Ren Hospital is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Tong Ren Hospital trials recruiting?

Yes. 5 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Tong Ren Hospital testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Azacitidine (2), Selinexor (2), Venetoclax (2) and Alirocumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.